Biotech Startups

2 investors

FluidForm Bio builds living human tissue using its FRESH 3D bioprinting technology, which forms tissue from cells and proteins for use in pharma, medical device, and regenerative medicine applications. The company partners with life science companies and combines 3D printing, computational and synthetic biology, AI, and materials science to develop tissue for treating disease.

2 investors

FluoretiQ develops rapid point-of-care diagnostic tools that identify bacteria and determine effective antibiotics for veterinarians and clinicians, aiming to reduce reliance on empirical antibiotic treatment. Its NANOPLEX latex agglutination platform underpins its first product, VERI-5 VET, and its SCFI platform provides growth-free antibiotic susceptibility testing.

2 investors

Foamlab develops bio-nanocellulose foam grown by microorganisms through fermentation, offering compostable, tunable alternatives to oil-based plastics and foams. Its materials target applications such as protective and thermal packaging, insulation, textiles and footwear, furniture, cosmetics, and aviation and automotive uses.

2 investors

FogPharma develops ultra-tunable Helicon peptide therapeutics designed to reach historically undruggable targets, aiming to treat cancer and other serious diseases. The company operates a custom-built research platform focused on this peptide modality for drug discovery.

2 investors

Forcefield Therapeutics develops cardioprotective proteins for the treatment of cardiac disease, with an initial focus on myocardial infarction (heart attack). It holds an exclusive licence to these proteins and operates a virtual business model working with strategic and operational partners.

2 investors

For Seafoods develops organoid technology to cultivate seafood at scale, offering a sustainable alternative to ocean fishing. The company's proprietary tissue formation method reduces production costs and enables commercially viable cultivated seafood for global consumers.

2 investors

FortePhest is a biotechnology company developing crop protection products, including its development-stage herbicide H-Forte, which uses a new mechanism of action targeting the enzyme Phenylalanine tRNA Synthetase to control both regular and herbicide-resistant weeds. Founded in 2017 and based on research from Cornell University, the Weizmann Institute of Science, and the Hebrew University of Jerusalem, it serves the agricultural crop protection market.

2 investors

Francis Medical is a medical device company developing minimally invasive urological cancer treatments using water vapor ablation technology, initially focused on prostate cancer with its Vanquish Water Vapor Ablation System. It plans to expand into bladder and kidney cancer applications, aiming to reduce the side effects associated with conventional prostate treatments.

2 investors

Fraunhofer is a research organization whose Institute for Toxicology and Experimental Medicine (ITEM) conducts contract research, including cell-based in vitro inhalation methods to assess respiratory effects of aerosols and identify potentially harmful substances without animal testing. Its work supports safe product development under a safe-by-design approach.

2 investors

Fulcrum Therapeutics develops small-molecule drugs targeting rare genetic diseases with significant unmet treatment needs, with its lead candidate pociredir in clinical testing for sickle cell disease as an oral therapy designed to increase fetal hemoglobin levels.

2 investors

Fusion Genomics' ONETest platform integrates targeted metagenomic sequencing with artificial intelligence-driven analysis to identify microbial pathogens from clinical specimens, serving hospital laboratories and critical-care teams for complex infection diagnosis.

2 investors

Future Cow uses precision fermentation to produce animal-free dairy proteins with the taste and texture of milk, sold as an ingredient to food industries. The proteins can be reconstituted into milk substitutes for making ice cream, cheese, and other dairy-based products without using animals.

2 investors

Gain Therapeutics is a biotechnology company that develops small molecule drugs targeting allosteric binding sites on disease-related proteins, using its computational Magellan platform to discover compounds that stabilize or destabilize proteins to treat central nervous system disorders, lysosomal storage diseases, metabolic disorders, and oncology; its lead candidate GT-02287 is in Phase 1b testing for Parkinson's disease.

2 investors

Isolation Bio (Galt Inc.) develops the Prospector Discovery Platform, a high-throughput, automated microbial cultivation array technology that isolates, cultivates, and screens thousands of microbes in parallel. It also offers a microbial isolation and cultivation service for researchers working on microbiome applications in human health, animal health, crop improvement, and environmental health.

2 investors

GAMGEE develops personalised mRNA cancer vaccines for dogs, created from the animal's own tumour tissue to help its immune system fight the cancer. The company manages the full process end to end—from diagnosis and tissue sampling with the pet owner's vet, to genomic analysis and treatment delivery via veterinary oncologists—and is currently running clinical trials in Australia while accepting applications globally.

2 investors

Ganymede provides a developer-friendly, open-source data platform that integrates and analyzes laboratory data for life science organizations. It helps scientists and developers at biotech and pharmaceutical companies manage lab data and make data-driven decisions across research, development, and manufacturing.

2 investors

GREEN VET provides diagnostic testing, health screening, and management services for companion animals, serving veterinarians and pet owners in South Korea. The company operates as a specialized animal healthcare provider offering laboratory diagnostics, digital pathology, and preventive care services.

2 investors

Gelesis develops an oral superabsorbent hydrogel platform (OHS) built from naturally derived materials that works locally in the GI tract to influence satiety signals and support metabolic health. Its product Plenity is a clinically studied aid for weight management in overweight or obese adults with a BMI of 25 to 40 when combined with diet and exercise.

2 investors

Precision medicine company developing therapeutics for genetically-defined age-related macular degeneration.

2 investors

Gene S is an Australian biotechnology company providing Next Generation Sequencing solutions and gene testing software to laboratories and healthcare providers for delivering pharmacogenomic results.

2 investors

Genedrive Diagnostics develops and commercialises a rapid point-of-care pharmacogenetic testing platform that detects genetic variants to guide personalised medicine decisions in emergency healthcare. The UK-based company's tests help clinicians tailor drug choices based on a patient's genetics.

2 investors

GenEmbryomics provides comprehensive preimplantation genetic screening of IVF embryos using whole genome sequencing, screening for chromosome abnormalities, mosaicism, and thousands of inherited and new genetic mutations. It serves patients and families undergoing IVF, delivering reports to help select embryos with the lowest genetic disease risk.

2 investors

GenePath Diagnostics is a molecular diagnostics company offering laboratory tests and assays for infectious diseases, cancers, and genetic disorders to medical professionals and patients. Established in India, the company provides rapid and sensitive molecular testing solutions positioned as more accessible and affordable than conventional diagnostic methods.

2 investors